Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

PURPOSE: VEGF is upregulated in glioblastoma and may contribute to immunosuppression. We performed a phase II study of pembrolizumab alone or with bevacizumab in recurrent glioblastoma. PATIENTS AND METHODS: Eighty bevacizumab-naïve patients with recurrent glioblastoma were randomized to pembrolizum...

Full description

Saved in:
Bibliographic Details
Published in:Clin Cancer Res
Main Authors: Nayak, Lakshmi, Molinaro, Annette M., Peters, Katherine, Clarke, Jennifer L., Jordan, Justin T., de Groot, John, Nghiemphu, Leia, Kaley, Thomas, Colman, Howard, McCluskey, Christine, Gaffey, Sarah, Smith, Timothy R., Cote, David J., Severgnini, Mariano, Yearley, Jennifer H., Zhao, Qing, Blumenschein, Wendy M., Duda, Dan G., Muzikansky, Alona, Jain, Rakesh K., Wen, Patrick Y., Reardon, David A.
Format: Artigo
Language:Inglês
Published: 2020
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8284901/
https://ncbi.nlm.nih.gov/pubmed/33199490
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-2500
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items